Recent trials with anifrolumab (94), which blocks type 1 interferon, and ongoing trials for Atacicept (blocks BAFF and APRIL) (95), demonstrate the possibility of success using approaches that are more precise in the treatment of SLE. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.